Market Cap (In USD)
115.57 Million
Revenue (In USD)
-
Net Income (In USD)
-36.94 Million
Avg. Volume
736.1 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 3.01-13.68
- PE
- -1.37
- EPS
- -1.32
- Beta Value
- 0.713
- ISIN
- US5171251003
- CUSIP
- 517125100
- CIK
- 1374690
- Shares
- 64027900.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Carole S. Ben-Maimon M.D.
- Employee Count
- -
- Website
- https://www.larimartx.com
- Ipo Date
- 2014-06-19
- Details
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
More Stocks
-
3808
-
7444
-
BAKBraskem S.A.
BAK
-
2918
-
7085
-
NDSNNordson Corporation
NDSN
-
RGP
-
ECPG